nejm tirzepatide In patients with type 2 diabetes and atherosclerotic cardiovascular disease, was noninferior to dulaglutide with respect to major cardiovascular events. ⁣, ⁣, Read the full SURPASS-CVOT In the SURMOUNT-1 trial (published

Combining compounds also compounds uncertainty: interaction data in humans is limited, and the absence of large trials means dosing conventions are largely empirical rather than evidence-based

This gives us a unique opportunity to provide the body with exactly what it needs so that it can continue to produce glutathione without interruption

S.DrewM

Prandial options to advance basal insulin glargine therapy: testing lixisenatide plus basal insulin versus insulin glulisine either as basal-plus or basal-bolus in type 2 diabetes: the GetGoal Duo-2 Trial

Liposomes containing ionizable groups alter their charge and characteristics in reaction to pH, resulting in drug release